Program Information


This non-CME symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.

Sunday, June 2, 2019
Lunch
12:45 PM – 1:00 PM ET

Panel-Based Faculty Discussions
1:00 PM – 2:15 PM ET



Sheraton Boston Hotel
Constitution Ballroom, 2nd Level
39 Dalton Street
Boston, MA 02199


PATIENT-CENTRIC SYMPOSIUM
Join us for a spirited clinical case-based discussion amongst world-renowned experts. Ask your challenging questions about antibody-mediated rejection (AMR) in renal transplant patients and learn about emerging therapies for improved patient outcomes.


PROGRAM AGENDA

12:45 PM – 1:00 PM
 
Lunch and Registration
1:00 PM – 1:10 PM
 
Welcome and Introductions
Robert A. Montgomery, MD, DPhil, FACS
1:10 PM – 1:25 PM
 
Clinical Case 1:
Renal Transplant Patient with Difficult-to-Treat AMR
Robert A. Montgomery, MD, DPhil, FACS and Full Panel
1:25 PM – 1:30 PM
 
Audience Q&A
All Faculty
1:30 PM – 1:45 PM
 
Clinical Case 2:
Renal Transplant Patient with Chronic Active AMR
Stanley C. Jordan, MD and Full Panel
1:45 PM – 1:50 PM
 
Audience Q&A
All Faculty
1:50 PM – 2:05 PM
 
Clinical Case 3:
Renal Transplant Patient with Refractory AMR
Fritz Diekmann, MD and Full Panel
2:05 PM – 2:15 PM
 
Audience Q&A and Closing
All Faculty

FACULTY PANEL

Robert A. Montgomery, MD, DPhil, FACS (Chair)
Professor of Surgery
Director, NYU Langone Transplant Institute
New York, NY (USA)
Fritz Diekmann, MD
Chief, Kidney Transplant Unit
Associate Professor
Hospital Clinic de Barcelona
Barcelona, Spain (EUROPE)
Stanley C. Jordan, MD
Director, Division of Nephrology
Medical Director, Kidney Transplant Program
Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
Cedars-Sinai Medical Center
Los Angeles, CA (USA)


LEARNING OBJECTIVES
After engaging in this activity, transplant clinicians will be able to:

  • Describe the pathophysiology of antibody-mediated rejection (AMR), including the significance of the activation of the complement system cytokine pathways, in order to effectively and aggressively institute treatment
  • Discuss existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
  • Select appropriate therapeutic agents and protocols to treat AMR and prolong allograft survival

INTENDED LEARNERS
Clinicians who manage antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).

PROVIDER STATEMENT
This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.


STATEMENT OF SUPPORT
This activity is supported by an independent educational grant from CSL Behring.


FEE INFORMATION
There is no fee for this educational activity.


QUESTIONS?
Please contact Nicole Fortune at nfortune@rmei.com if you have any questions.




FOLLOW RMEI
Facebook  Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.